April 26, 2024
PANDA (Pan autoantibody negative diabetes in adults) study
Seminar 15, Beyond Insulin Seminar Series – Dr Shivani Patel from the Garvan Institute of Medical Research will present ‘PANDA (Pan autoantibody negative diabetes in adults) study’.
Read more
March 28, 2024
Lessons from a failed coeliac disease trial: a new way forwards?
Seminar 14, Beyond Insulin Seminar Series – Associate Professor Jason Tye-Din from WEHI will present ‘Lessons from a failed coeliac disease trial: a new way forwards?’
Read more
February 23, 2024
Using Type 1 Diabetes Genetic Risk Scores for Prediction and Diagnosis of Type 1 Diabetes
Seminar 13, Beyond Insulin Seminar Series – Dr Maria Redondo from Baylor College of Medicine, Houston, Texas provides an update on T1D Genetic Risk Scores in T1D
Read more
November 23, 2023
Research breakthrough
December 2023
In a world-first, ATIC researchers lead by Professor’s Thomas Kay and Helen Thomas have shown that baricitinib, an immunotherapy treatment commonly used in rheumatoid arthritis, can delay the progression of type 1 diabetes…
Read more
November 23, 2023
CD47 – more than just a receptor on islets
Seminar 12 in the Beyond Insulin Seminar Series will be a summary of the findings from a recent discovery in CD47 receptors and type 1 diabetes by Professor Natasha Rogers (Westmead Hospital).
Read more
October 27, 2023
Checkpoint inhibitor related autoimmune diabetes: from bench to bedside
Seminar 11 – Beyond Insulin Seminar Series, Dr Linda Wu from Westmead Institute for Medical Research provides an update on current knowledge around checkpoint inhibitor related diabetes
Read more
T1D RELAY – New clinical trial now open
September 2023
ATIC and The Royal Melbourne Hospital are now seeking people aged 8-45 years with recently diagnosed type 1 diabetes (within three months) for a new clinical trial of two disease-modifying medications rituximab-pvvr and abatacept, called T1D RELAY.
Read more
September 21, 2023
Who killed my beta cells and why did they do it?
Seminar 10 of the Beyond Insulin Seminar Series features Associate Professor Stuart Mannering who will discuss one of the fundamental outstanding questions in the immunology of T1D – how and why does the immune system attack the insulin producing cells?
Read more
July 27, 2023
Role of the gut microbiota in T1D
Seminar 9 of the Beyond Insulin Seminar Series features Associate Professor Emma Hamilton-Williams. A/Prof Hamilton-Williams will discuss results from a clinical trial that aimed to restore a ‘healthy’ gut microbiota in adults with type 1 diabetes.
Read more
All trial sites for the Nasal Insulin and Abatacept (IAA Trial) are now open
June 2023
For the first time in Australia, researchers will carry out a type 1 diabetes trial to test two different immune therapies in children and young adults who have been recently diagnosed with type 1 diabetes.
Read more
April 28, 2023
Viral aetiology of type 1 diabetes
7th seminar in the ‘Beyond Insulin: Innovative research in T1D prevention and cure’ seminar series
Read more
Verapamil in type 1 diabetes
March 2023
The human immune system works every minute of every day to keep the body healthy – through constant monitoring, and by tracking and destroying pathogens, such as disease-causing bacteria and viruses.
Read more
March 23, 2023
Continuous glucose monitoring in children at risk of type 1 diabetes
6th seminar in the ‘Beyond Insulin: Innovative research in T1D prevention and cure’ seminar series
Read more
February 22, 2023
ATIC Town Hall Forum – video now available
ATIC recently invited members of the type 1 diabetes community to learn more about ATIC – the first Australasian clinical trial collaborative set up to accelerate development and delivery of immunotherapy treatments.
Read more
February 24, 2023
Baricitinib in the Treatment of Alopecia Areata
5th seminar in the ‘Beyond Insulin: Innovative research in T1D prevention and cure’ seminar series
Read more
IAA clinical trial now open for recruitment
January 2023
ATIC is now seeking participants aged between 6 and 21 years with newly diagnosed type 1 diabetes for a ground-breaking Australian clinical trial.
Read more
Community Engagement Panel – calling for expressions of interest
November 2022
ATIC is seeking expressions of interest from members of the type 1 diabetes community who are interested in joining our Community Engagement Panel.
Read more October 28, 2022
Benchmarking cells for beta cell replacement therapies
3rd seminar in the ‘Beyond Insulin: Innovative research in T1D prevention and cure’ seminar series
Read more September 29, 2022
Harnessing T cell exhaustion to treat autoimmune disease
2nd seminar in the ‘Beyond Insulin: Innovative research in T1D prevention and cure’ seminar series
Read more August 26, 2022
New ATIC Seminar Series: commencing 26th August 2022
Introducing ATIC’s new seminar series ‘Beyond Insulin: Innovative research in T1D prevention and cure’. Join us for a new session each month!
Read more
August 10, 2022
August ATIC launch at Australian Diabetes Congress
We’re very excited to be officially launching ATIC at the upcoming ADC 2022 in Brisbane.
Read more
ATIC Steering Committee meet for the first time
April 2022
Leading diabetes clinicians and researchers from across Australia gathered recently for the first meeting of the Australasian Type 1 Diabetes Immunotherapies Collaborative (ATIC) Steering Committee.
Read more
Immunotherapy: harnessing our immune system against disease
March 2022
The human immune system works every minute of every day to keep the body healthy – through constant monitoring, and by tracking and destroying pathogens, such as disease-causing bacteria and viruses.
Read more
IMPACT trial commences in Australia
February 2022
In collaboration with Innodia, the ATIC network is leading IMPACT, a trial of a new medication called IMCY-0098 to determine whether it can preserve pancreas function in people with newly diagnosed type 1 diabetes.
Read more
BANDIT trial filled
January 2022
Thanks to the generosity of the type 1 diabetes community, we have completed recruitment for the BANDIT trial.
Read more
Collaborative focused on immunotherapy in type 1 diabetes – ANZ first
January 2022
JDRF Australia has funded a first-of-its kind four-year collaboration, aimed at increasing the number of clinical trials available for Australians with type 1 diabetes.
Read more